Understanding responses to an organizational takeover: Introducing the social identity model of organizational change.
- Published in:
- 2022
- By:
- Publication type:
- Journal Article
Works matching DE "PHARMACEUTICAL industry"
Results: 5000
1
2
Review of <i>Saving talk therapy: How health insurers, big pharma, and slanted science are ruining good mental health care</i>.
- Published in:
- 2019
- By:
- Publication type:
- Review-Book
3
'A progressive downward spiral': The circulation of risk in 'bipolar disorder'.
- Published in:
- 2013, isbn. 978-1-4338-1668-0
- By:
- Publication type:
- Journal Article
4
Academic detailing.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
5
Latent class models for marketing strategies: An application to the Italian pharmaceutical market.
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
6
Direct-to-consumer advertising of psychotropic medication and prescription authority for psychologists.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
7
Is there a future for clinical psychology?
- Published in:
- 2007
- By:
- Publication type:
- Editorial
8
The Pharmaceutical Industry's Use of Gifts and Educational Events to Influence Prescription Practices: Ethical Dilemmas and Implications for Psychologists.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
9
Psychology in the Prescription Era: Building a Firewall Between Marketing and Science.
- Published in:
- 2003
- By:
- Publication type:
- Journal Article
10
Saving our psychosocial souls.
- Published in:
- 2004
- By:
- Publication type:
- Comment/Reply
11
Loren Mosher: In memoriam.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
12
Clinical research and the Third World.
- Published in:
- 2001
- By:
- Publication type:
- Editorial
13
Drug-company influence on medical education in the U.S.A.
- Published in:
- 2001
- By:
- Publication type:
- Comment/Reply
14
Facilitating Objectivity When Orchestrating the Interaction Between Pharmacotherapy and Psychotherapy.
- Published in:
- 2004
- By:
- Publication type:
- Comment/Reply
15
Poly-drug abuse: Drug companies and doctors.
- Published in:
- 1973
- By:
- Publication type:
- Column/Opinion
16
Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector.
- Published in:
- Marine Drugs, 2025, v. 23, n. 5, p. 207, doi. 10.3390/md23050207
- By:
- Publication type:
- Article
17
IW-Studie: „Hemmschuh für Pharmastandort Deutschland".
- Published in:
- Pharma + Food, 2025, p. 10
- Publication type:
- Article
18
Interview mit Dr. Olaf Weinmann zum Cyber Resilience Act.
- Published in:
- Pharma + Food, 2025, p. 24
- Publication type:
- Article
19
CEOs von Novartis und Sanofi : „Wir hoffen, dass Europa die Gunst der Stunde nutzt.".
- Published in:
- Pharma + Food, 2025, p. 8
- Publication type:
- Article
20
Heimische Märkte wieder mehr im Fokus.
- Published in:
- Pharma + Food, 2025, p. 6
- Publication type:
- Article
21
Top 5 Beiträge.
- Published in:
- Pharma + Food, 2025, p. 8
- Publication type:
- Article
22
Körber verbindet globale Standards mit lokaler ExpertiseNahtlose Sekundärverpackungs-Lösungen weltweit.
- Published in:
- Pharma + Food, 2025, p. 22
- Publication type:
- Article
23
Rezeptursoftware macht Pharmaproduktion sicherer und effizienter.
- Published in:
- Pharma + Food, 2025, p. 60
- Publication type:
- Article
24
Effizient statt überlastet.
- Published in:
- Pharma + Food, 2025, p. 64
- Publication type:
- Article
25
Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?
- Published in:
- Cancers, 2025, v. 17, n. 10, p. 1722, doi. 10.3390/cancers17101722
- By:
- Publication type:
- Article
26
The advisory body on animal ethics of a global pharmaceutical company: A global organization to address ethical and societal concerns about animal use.
- Published in:
- Laboratory Animals, 2025, v. 59, n. 3, p. 390, doi. 10.1177/00236772241302537
- By:
- Publication type:
- Article
27
Unlocking access: a comprehensive analysis of medicines accessibility for rare diseases in Thailand.
- Published in:
- Orphanet Journal of Rare Diseases, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13023-025-03754-9
- By:
- Publication type:
- Article
28
A facile, scalable, and sustainable approach to the preparation of the indole-core of alectinib.
- Published in:
- Bulletin of the Chemical Society of Japan, 2025, v. 98, n. 3, p. 1, doi. 10.1093/bulcsj/uoaf019
- By:
- Publication type:
- Article
29
Announcements.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 7, p. 571
- Publication type:
- Article
30
Announcements.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1634
- Publication type:
- Article
31
Small Steps Forward in the Land of Small Tumors.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1623
- By:
- Publication type:
- Article
32
New Formulation of BLP25 Liposome Vaccine: Phase II Study Interim Results.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 13, p. 1682
- Publication type:
- Article
33
Announcements.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 9, p. 1117
- Publication type:
- Article
34
What's in the Pipeline?
- Published in:
- RT: The Journal for Respiratory Care Practitioners, 2011, v. 24, n. 7, p. 29
- Publication type:
- Article
35
Conflict-Free?
- Published in:
- 2009
- By:
- Publication type:
- Editorial
36
Dividend policy issues in the European pharmaceutical industry: new empirical evidence.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 5, p. 803, doi. 10.1007/s10198-022-01510-5
- By:
- Publication type:
- Article
37
How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach.
- Published in:
- European Journal of Health Economics, 2021, v. 22, n. 5, p. 699, doi. 10.1007/s10198-021-01284-2
- By:
- Publication type:
- Article
38
Efficiency ratio and rocketing drug prices: old concerns and new possibilities.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
39
International impact of external reference pricing: should national policy-makers care?
- Published in:
- 2019
- By:
- Publication type:
- journal article
40
Conflict of interest disclosure: striking a balance?
- Published in:
- 2019
- By:
- Publication type:
- Editorial
41
Pharmaceutical pricing conundrum: time to get rid of it?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
42
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
- Published in:
- 2018
- By:
- Publication type:
- journal article
43
A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
44
Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
45
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
46
Corruption costs lives: evidence from a cross-country study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
47
Competition in pharmaceuticals: more product- than price-oriented?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
48
Why trash don't pass? pharmaceutical licensing and safety performance of drugs.
- Published in:
- 2017
- By:
- Publication type:
- journal article
49
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
- Published in:
- 2017
- By:
- Publication type:
- journal article
50
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.
- Published in:
- 2016
- By:
- Publication type:
- journal article